In last trading session, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) saw 63331.0 shares changing hands with its beta currently measuring 0.27. Company’s recent per share price level of $2.09 trading at -$0.14 or -6.28% at ring of the bell on the day assigns it a market valuation of $11.92M. That closing price of BCLI’s stock is at a discount of -468.9% from its 52-week high price of $11.89 and is indicating a premium of 49.76% from its 52-week low price of $1.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 83010.0 shares which gives us an average trading volume of 113.21K if we extend that period to 3-months.
For Brainstorm Cell Therapeutics, Inc (BCLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
Upright in the red during last session for losing -6.28%, in the last five days BCLI remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $2.09 price level, adding 11.81% to its value on the day. Brainstorm Cell Therapeutics, Inc’s shares saw a change of -7.93% in year-to-date performance and have moved -7.93% in past 5-day. Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) showed a performance of 31.45% in past 30-days. Number of shares sold short was 0.11 million shares which calculate 1.25 days to cover the short interests.
Brainstorm Cell Therapeutics, Inc (BCLI) estimates and forecasts
Statistics highlight that Brainstorm Cell Therapeutics, Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -60.30% of value to its shares in past 6 months, showing an annual growth rate of 60.65% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.56% during past 5 years.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
Insiders are in possession of 9.04% of company’s total shares while institution are holding 13.90 percent of that, with stock having share float percentage of 15.28%. Investors also watch the number of corporate investors in a company very closely, which is 13.90% institutions for Brainstorm Cell Therapeutics, Inc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at BCLI for having 7.92 million shares of worth $2.68 million. And as of 2024-06-30, it was holding 12.2302 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.51 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.3334 of outstanding shares, having a total worth of $0.51 million.
